Patents by Inventor Scott A. Shaw

Scott A. Shaw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RXFP1 agonists
    Patent number: 12709594
    Abstract: The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension).
    Type: Grant
    Filed: October 28, 2022
    Date of Patent: August 18, 2026
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald J. P. Pinto, Shun Su, Arvind Mathur, Michael C. Myers, Jianqing Li, Kumar Balashanmuga Pabbisetty, Scott A. Shaw
  • RXFP1 AGONISTS
    Publication number: 20250268903
    Abstract: The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension).
    Type: Application
    Filed: October 28, 2022
    Publication date: August 28, 2025
    Inventors: Scott A. Shaw, Adam James Clarke, Todd J. Friends, Arvind Mathur, Michael C. Myers, Jianqing Li, Kumar Balashanmuga Pabbisetty, Shun Su, George O. Tora, Benjamin P. Vokits, Laxman Pasunoori
  • RXFP1 AGONISTS
    Publication number: 20250221966
    Abstract: The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension).
    Type: Application
    Filed: October 28, 2022
    Publication date: July 10, 2025
    Inventors: Shun Su, Donna M. Bilder, Adam James Clarke, Heather Finlay, Todd J. Friends, Arvind Mathur, Michael C. Myers, R. Michael Lawrence, Jianqing Li, Donald J.P. Pinto, Michael J. Orwat, Kumar Balashanmuga Pabbisetty, Scott A. Shaw, Leon M. Smith, II, George O. Tora, Benjamin P. Vokits, Daniel O'Malley, Nicholas R. Wurtz, Vikram Bhogadi, Laxman Pasunoori, Pitani Veera Venkata Srinivas, Sreekantha Ratna Kumar, Hima Kiran Potturi, Subramanya Hegde
  • RXFP1 AGONISTS
    Publication number: 20250011288
    Abstract: The disclosure relates to compounds of Formula (I), which arm RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension).
    Type: Application
    Filed: October 28, 2022
    Publication date: January 9, 2025
    Inventors: Adam James Clarke, Todd J. Friends, Arvind Mathur, Michael C. Myers, Jianqing Li, Donald J. P. Pinto, Kumar Balashanmuga Pabbisetty, Shun Su, Benjamin P. Vokits, Durga Buchi Raju Barre, Leon M. Smith, II, Michael J. Orwat, Scott A. Shaw, Sreekantha Ratna Kumar, Hima Kiran Potturi
  • RXFP1 AGONISTS
    Publication number: 20240417369
    Abstract: The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension).
    Type: Application
    Filed: October 28, 2022
    Publication date: December 19, 2024
    Inventors: Donald J. P. Pinto, Shun Su, Arvind Mathur, Michael C. Myers, Jianqing Li, Kumar Balashanmuga Pabbisetty, Scott A. Shaw
  • Spiroheptanyl hydantoins as ROCK inhibitors
    Patent number: 12060341
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: August 16, 2022
    Date of Patent: August 13, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Benjamin P. Vokits, Scott A. Shaw
  • SPIROHEPTANYL HYDANTOINS AS ROCK INHIBITORS
    Publication number: 20240092755
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: August 16, 2022
    Publication date: March 21, 2024
    Inventors: Benjamin P. Vokits, Scott A. Shaw
  • Spiroheptanyl hydantoins as rock inhibitors
    Patent number: 11447487
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: September 20, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Benjamin P. Vokits, Scott A. Shaw
  • Triazolopyridine inhibitors of myeloperoxidase
    Patent number: 11059818
    Abstract: The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: July 13, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joanne M. Smallheer, Carol Hui Hu, Meriah Neissel Valente, Scott A. Shaw, Benjamin P. Vokits, Oz Scott Halpern
  • SPIROHEPTANYL HYDANTOINS AS ROCK INHIBITORS
    Publication number: 20210155618
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: July 11, 2018
    Publication date: May 27, 2021
    Inventors: Benjamin P. Vokits, Scott A. Shaw
  • Triazolopyridine inhibitors of myeloperoxidase and/or EPX
    Patent number: 11008317
    Abstract: The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: May 18, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ellen K. Kick, Joanne M. Smallheer, Scott A. Shaw, Benjamin P. Vokits, Andrew K. Dilger, Charles G. Clark, Meriah Neissel Valente, Sutjano Jusuf, Nicholas R. Wurtz
  • Spiroheptane salicylamides and related compounds as inhibitors of ROCK
    Patent number: 10829501
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: November 10, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Leon M. Smith, II, Vladimir Ladziata, Indawati DeLucca, Donald J. P. Pinto, Michael J. Orwat, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, Wu Yang, Scott A. Shaw, Peter W. Glunz, Manoranjan Panda
  • TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE
    Publication number: 20200291015
    Abstract: The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: March 10, 2017
    Publication date: September 17, 2020
    Inventors: Joanne M. Smallheer, Carol Hui HU, Meriah Neissel Valente, Scott A. Shaw, Benjamin P. Vokits, Oz Scott Halpern
  • TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX
    Publication number: 20200291016
    Abstract: The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: March 16, 2017
    Publication date: September 17, 2020
    Inventors: Ellen K. Kick, Joanne M. Smalheer, Scott A. Shaw, Benjiman P. Vokits, Andrew K. Dilger, Charles G. Clark, Meriah Neissel Valente, Sutjano Jusuf, Nicholas R. Wurtz
  • SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK
    Publication number: 20200131200
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: January 10, 2020
    Publication date: April 30, 2020
    Inventors: Leon M. Smith, II, Vladimir Ladziata, Indawati De Lucca, Donald J.P. Pinto, Michael J. Orwat, Andrew K. Dilger, Kumar Balashnmuga Pabbisetty, Wu Yang, Scott A. Shaw, Peter W. Glunz, Manoranjan Panda
  • Spiroheptane salicylamides and related compounds as inhibitors of rock
    Patent number: 10611776
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: April 7, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Leon M. Smith, II, Vladimir Ladziata, Indawati De Lucca, Donald J. P. Pinto, Michael J. Orwat, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, Wu Yang, Scott A. Shaw, Peter W. Glunz, Manoranjan Panda
  • Triazolopyridine inhibitors of myeloperoxidase
    Patent number: 10407422
    Abstract: The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: September 10, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joanne M. Smallheer, Scott A. Shaw, Oz Scott Halpern, Carol Hui Hu, Ellen K. Kick
  • Triazolopyridine inhibitors of myeloperoxidase
    Patent number: 10316035
    Abstract: The present invention provides compounds of Formula (I): wherein A, Y and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: June 11, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew Quoc Viet, Nicholas Ronald Wurtz, Scott A. Shaw, Ellen K. Kick, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty
  • Triazolopyridine inhibitors of myeloperoxidase
    Patent number: 10214527
    Abstract: The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: February 26, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Scott A. Shaw, Joanne M. Smallheer
  • TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE
    Publication number: 20190023701
    Abstract: The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Application
    Filed: August 30, 2016
    Publication date: January 24, 2019
    Inventors: Joanne M. Smallheer, Scott A. Shaw, Oz Scott Halpern, Carol Hui Hu, Ellen K. Kick